Southern Shuanglin Bio-Pharmacy halted amid control change plans

Southern Shuanglin Bio-Pharmacy announced a halt in trading of its shares, effective from market open on June 6, 2025, as its controlling shareholder, Gongqingcheng Shengbang Yinghao Investment Partnership (limited partnership), is planning a change of control. The company anticipates the suspension will last no more than two trading days. The company cautions investors that the matter is still in the planning stages, and is subject to significant uncertainty. Southern Shuanglin Bio-Pharmacy will disclose further information as required by regulations, with official announcements to be published in the Securities Times and on the Cninfo website (www.cninfo.com.cn). The company advises investors to pay close attention to subsequent announcements and be mindful of investment risks.